Molnupiravir, the new name for N4-hydroxycytidine, a molecule that produces mutations in all living things, this again violates the nuremberg code, will anyone go to trial for this?

The first at-home treatment for Covid has been given to patients in the UK as part of a major national study.

Molnupiravir will be tested on 10,000 people at risk of serious illness in research led by University of Oxford.

Last month, the UK became the first country in the world to approve its use - a move described as a "game-changer" by health secretary Sajid Javid.

But some scientists have questioned its effectiveness after its early clinical trial results were downgraded.

'More at risk'

Molnupiravir, initially developed to treat influenza, works by inserting errors into the genetic code of coronavirus every time it copies itself, limiting its ability to multiply in the body.

The UK has agreed to purchase 480,000 courses of the drug which is designed to reduce the risk of more vulnerable patients needing hospital treatment after catching the virus.

Souce